Interim report Q1 2024
Business Highlights during the first quarter 2024 · Announcing the achievement of the first milestone under the agreement with Curium Inc. to develop uTRACE[®] for improving diagnosis of prostate cancer. · The Company remains committed to accelerating its therapeutic strategy and is currently evaluating alternative financing options. · After the end of Q1 the Company received acceptance of the clinical trial application from the European Medicines Agency for the investigation of uTRACE[®] in a phase 2 trial.Copenhagen, Denmark, 23 May 2024 - Curasight A/S (“Curasight” or “the